Title: A nomogram for predicting cancer-specific survival for elderly patients with gallbladder
cancer
Version: 1 Date: 05 May 2022
Reviewer's report:
Dr. Wen and co-authors present a study of building a nomogram for predicting cancer-specific
survival for elderly patients with gallbladder.
Here I present a few concerns regarding their paper:
1. In SEER database, some patients were based on TNM 6th edition, some were based on TNM
7th edition. The information in 'Derived.AJCC.7.T', 'Derived.AJCC.7.N', 'Derived.AJCC.7.M'
were based on TNM 7th edition. The information in 'Derived.AJCC.T', 'Derived.AJCC.N',
'Derived.AJCC.M' were based on the TNM 6th edition. However, the TNM 8th edition
information were missing in the original data. How to unify the consistency?
2. This study were aimed for elderly GBD patients. Why choose the age 65 for elderly patients?
Is it randomly defined?
3. As for external validation, we usually include the patient cohort from a different affiliation.
However, in this study, the author used the patients in the same cohort from 2016 to 2018
for external validation. There might be bias, since the development of surgery skill and
chemotherapy might improve the overall survival of GBD patients from 2016 to 2018, compared
with patients from 2004 to 2015.
4. The factor of chemotherapy, some patients were identified as "yes", some patients were
identified as "No / Unknown". It was not accurate. The "unknown" patients should be excluded.
Title: A nomogram for predicting cancer-specific survival for elderly patients with gallbladder
cancer
Version: 1 Date: 05 May 2022
Reviewer's report:
Dr. Wen and co-authors present a study of building a nomogram for predicting cancer-specific
survival for elderly patients with gallbladder.
Here I present a few concerns regarding their paper:
1. In SEER database, some patients were based on TNM 6th edition, some were based on TNM
7th edition. The information in 'Derived.AJCC.7.T', 'Derived.AJCC.7.N', 'Derived.AJCC.7.M'
were based on TNM 7th edition. The information in 'Derived.AJCC.T', 'Derived.AJCC.N',
'Derived.AJCC.M' were based on the TNM 6th edition. However, the TNM 8th edition
information were missing in the original data. How to unify the consistency?
2. This study were aimed for elderly GBD patients. Why choose the age 65 for elderly patients?
Is it randomly defined?
3. As for external validation, we usually include the patient cohort from a different affiliation.
However, in this study, the author used the patients in the same cohort from 2016 to 2018
for external validation. There might be bias, since the development of surgery skill and
chemotherapy might improve the overall survival of GBD patients from 2016 to 2018, compared
with patients from 2004 to 2015.
4. The factor of chemotherapy, some patients were identified as "yes", some patients were
identified as "No / Unknown". It was not accurate. The "unknown" patients should be excluded.
Please review this paper.
user
Title: A nomogram for predicting cancer-specific survival for elderly patients with gallbladder
cancer
Version: 1 Date: 05 May 2022
Reviewer's report:
Dr. Wen and co-authors present a study of building a nomogram for predicting cancer-specific
survival for elderly patients with gallbladder.
Here I present a few concerns regarding their paper:
1. In SEER database, some patients were based on TNM 6th edition, some were based on TNM
7th edition. The information in 'Derived.AJCC.7.T', 'Derived.AJCC.7.N', 'Derived.AJCC.7.M'
were based on TNM 7th edition. The information in 'Derived.AJCC.T', 'Derived.AJCC.N',
'Derived.AJCC.M' were based on the TNM 6th edition. However, the TNM 8th edition
information were missing in the original data. How to unify the consistency?
2. This study were aimed for elderly GBD patients. Why choose the age 65 for elderly patients?
Is it randomly defined?
3. As for external validation, we usually include the patient cohort from a different affiliation.
However, in this study, the author used the patients in the same cohort from 2016 to 2018
for external validation. There might be bias, since the development of surgery skill and
chemotherapy might improve the overall survival of GBD patients from 2016 to 2018, compared
with patients from 2004 to 2015.
4. The factor of chemotherapy, some patients were identified as "yes", some patients were
identified as "No / Unknown". It was not accurate. The "unknown" patients should be excluded.
assistant